Research programme: anti-phosphatidylserine monoclonal antibodies - Avid Bioservices

Drug Profile

Research programme: anti-phosphatidylserine monoclonal antibodies - Avid Bioservices

Alternative Names: 2aG4; Anti-phosphatidylethanolamine monoclonal antibodies - Avid Bioservices; Anti-phospholipid monoclonal antibodies - Avid Bioservices; ch1N11; PGN-502; PGN-503; PGN-504; Truncated tissue factors - Avid Bioservices; Vascular targeting agents - Avid Bioservices

Latest Information Update: 28 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center; University of Texas Southwestern Medical Center
  • Developer Avid Bioservices; Peregrine Pharmaceuticals
  • Class Diagnostic agents; Monoclonal antibodies
  • Mechanism of Action Diagnostic imaging enhancers; Immunostimulants; Magnetic resonance imaging enhancers; Phosphatidylserine receptor antagonists; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Malignant melanoma
  • No development reported Brain cancer; Breast cancer; Cancer; Non-small cell lung cancer; Prostate cancer

Most Recent Events

  • 28 May 2018 No recent reports of development identified for preclinical development in Non-small-cell-lung-cancer in USA (Parenteral)
  • 12 Feb 2018 Oncologie acquires anti-phosphatidylserine monoclonal antibodies from Avid Bioservices
  • 05 Jan 2018 Peregrine Pharmaceuticals is now called Avid Bioservices
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top